CVRXCVRx Inc. Common Stock

U.S. heart failure revenue surged 21% amid reimbursement gains and sales expansion challenges.

CVRx (NASDAQ:CVRX) outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during Canaccord Genuity’s 46th Annual Growth Conference. President and CEO Kevin Hykes sa

Moby summary of CVRx, Inc.'s Q2 2026 earnings call

Despite a 16% revenue increase and improved gross margins, CVRx lowers full-year guidance as sales force turnover and payer headwinds dampen growth.

CVRx (CVRX) delivered earnings and revenue surprises of -1.92% and +0.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CVRx (NASDAQ:CVRX) reported second-quarter revenue growth and an improved gross margin, but lowered its full-year outlook as sales-force turnover, slower productivity ramps and reimbursement challenges with a large Medicare Advantage payer are expected to weigh on results in the second half of 2026.

While the top- and bottom-line numbers for CVRx (CVRX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -4.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CVRX stock gains after Humana adds Medicare Advantage coverage for Barostim therapy, boosting reimbursement momentum and patient access.